WASHINGTON, D.C. -- The Food and Drug Administration (FDA) has received reports of potential distribution of unlicensed influenza vaccine in the United States. The agency is aggressively working with state health authorities and the Centers for Disease Control and Prevention (CDC) to investigate the source and quality of influenza vaccine being made available through unusual suppliers.
Specifically, the FDA has received reports of offers to sell unlicensed influenza vaccine in the U.S., and of individuals who are not licensed healthcare professionals administering questionable influenza vaccine in apparent efforts to take advantage of reports that influenza vaccine is in short supply. The FDA is actively investigating these reports and taking prompt action, when appropriate. For example, the FDA and the Florida Department of Health worked together to prevent unlicensed product from entering the country and being offered for sale.
The FDA has licensed three influenza vaccines for use in the U.S.: Fluzone, manufactured by Aventis Pasteur, Inc., and Fluvirin, manufactured by Evans Vaccines (a subsidiary of Chiron Corporation), both of which are given as injections; and FluMist, manufactured by Medimmune, which is given as a nasal spray. These vaccines are available from licensed sources, such as doctors, pharmacies and health care clinics.
CDC continues to work closely with FDA to obtain additional quantities of licensed influenza vaccine. Consumers with questions about flu vaccination itself, including who should be vaccinated or where to receive the vaccine, should ask a doctor or pharmacist. In addition, information is available on the FDA website at http://www.fda.gov/cber/flu/flu.htm, or the CDC website at http://www.cdc.gov/flu/.
To help assure that the influenza vaccine Americans receive is safe and effective, the FDA recommends that healthcare providers purchase the vaccine from reliable sources. Careful discretion should be used in determining whether the vaccine is being sold by reputable distributors with proper evidence that the vaccine is licensed for sale in the United States. Likewise, it is also recommended that consumers obtain influenza vaccine from licensed healthcare providers only. Healthcare professionals and consumers should report any suspicious offers or practices to FDA or local health authorities.
Source: FDA
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.